Biogen Idec Offers Profits, Buybacks, But Mixed Messages on Tysabri
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech says its closely-watched MS drug Tysabri helped drive better than expected profits, but admitted it might need a new safety label.
You may also be interested in...
R&D, In Brief
GSK starts second darapladib Phase III study: GlaxoSmithKline's second Phase III trial of its Lp-PLA2 inhibitor darapladib will evaluate long-term treatment with the first-in-class agent, which targets an enzyme linked to atherosclerotic plaque. The SOLID-TIMI 52 (Stabilization of Plaque using Darapladib-Thrombolysis in Myocardial Infarction) study started enrolling 11,500 patients with acute coronary syndrome, the firm announced Dec. 9. Darapladib, in combination with standard of care (which may include a statin, aspirin and blood pressure medications) will be compared to placebo, to assess the impact on cardiovascular events after starting treatment within 30 days of an ACS. The company started its first Phase III trial for the anti-atherosclerosis medication in late 2008, the 15,000-patient STABILITY trial in patients with chronic coronary artery disease is also tracking major cardiovascular events. With the darapladib clinical program, GSK has opted to conduct outcomes trials for the registrational studies, acknowledging the regulatory reality that particularly in the cardiovascular setting, FDA favors the more definitive morbidity and mortality data - as opposed to evidence of effect on surrogate endpoints - for its approval decisions (1Pharmaceutical Approvals Monthly, January 2009). The first trial is projected to report out in late 2011, although as an event-driven trial the timeline is uncertain. GSK reports that STABILITY completed patient enrollment ahead of schedule, and in October the firm announced that the trial had passed an interim safety analysis, primarily concerned with blood pressure effects
R&D, In Brief
GSK starts second darapladib Phase III study: GlaxoSmithKline's second Phase III trial of its Lp-PLA2 inhibitor darapladib will evaluate long-term treatment with the first-in-class agent, which targets an enzyme linked to atherosclerotic plaque. The SOLID-TIMI 52 (Stabilization of Plaque using Darapladib-Thrombolysis in Myocardial Infarction) study started enrolling 11,500 patients with acute coronary syndrome, the firm announced Dec. 9. Darapladib, in combination with standard of care (which may include a statin, aspirin and blood pressure medications) will be compared to placebo, to assess the impact on cardiovascular events after starting treatment within 30 days of an ACS. The company started its first Phase III trial for the anti-atherosclerosis medication in late 2008, the 15,000-patient STABILITY trial in patients with chronic coronary artery disease is also tracking major cardiovascular events. With the darapladib clinical program, GSK has opted to conduct outcomes trials for the registrational studies, acknowledging the regulatory reality that particularly in the cardiovascular setting, FDA favors the more definitive morbidity and mortality data - as opposed to evidence of effect on surrogate endpoints - for its approval decisions (1Pharmaceutical Approvals Monthly, January 2009). The first trial is projected to report out in late 2011, although as an event-driven trial the timeline is uncertain. GSK reports that STABILITY completed patient enrollment ahead of schedule, and in October the firm announced that the trial had passed an interim safety analysis, primarily concerned with blood pressure effects
Elan Moves Ahead With J&J Deal, But Does Biogen Really Approve?
Is it over? Elan Corp. and Johnson & Johnson said Sept. 17 they successfully closed their deal to share Alzheimer disease programs